Author
Kevadiya, Bhavesh DMachhi, Jatin
Herskovitz, Jonathan
Oleynikov, Maxim D
Blomberg, Wilson R
Bajwa, Neha
Soni, Dhruvkumar
Das, Srijanee
Hasan, Mahmudul
Patel, Milankumar
Senan, Ahmed M
Gorantla, Santhi
McMillan, JoEllyn
Edagwa, Benson
Eisenberg, Robert
Gurumurthy, Channabasavaiah B
Reid, St Patrick M
Punyadeera, Chamindie
Chang, Linda
Gendelman, Howard E
Date
2021-01-06Journal
Journal of NeuroImmune PharmacologyPublisher
Springer NatureType
ArticleOther
Metadata
Show full item recordAbstract
The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2. Graphical abstract: [Figure not available: see fulltext.].Identifier to cite or link to this item
http://hdl.handle.net/10713/14375ae974a485f413a2113503eed53cd6c53
10.1007/s11481-020-09968-x